Literature DB >> 12382527

Potential of DMXAA combination therapy for solid tumors.

Bruce C Baguley1, William R Wilson.   

Abstract

DMXAA is one of the first examples of a new class of anticancer agents that attack existing tumor blood vessels and thus deprives tumor tissue of an adequate blood supply. Its mechanism of action appears to rely on the induction within tumor tissue of cytokines, such as tumor necrosis factor. In experimental tumors, DMXAA interacts productively with radiation, hyperthermia and a number of chemotherapeutic drugs. This review discusses the mechanisms underlying such interactions and how these might be exploited in clinical cancer treatment.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12382527     DOI： 10.1586/14737140.2.5.593

Source DB:  PubMed          Journal:  Expert Rev Anticancer Ther        ISSN： 1473-7140            Impact factor:   4.512


  7 in total

Review 1.  The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting Agents.

Authors:  Dietmar W Siemann
Journal:  Cancer Treat Rev       Date:  2010-06-08       Impact factor: 12.111

Review 2.  Temporal aspects of the action of ASA404 (vadimezan; DMXAA).

Authors:  Bruce C Baguley; Dietmar W Siemann
Journal:  Expert Opin Investig Drugs       Date:  2010-11       Impact factor: 6.206

3.  Activity of the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid against human head and neck carcinoma xenografts.

Authors:  Mukund Seshadri; Richard Mazurchuk; Joseph A Spernyak; Arup Bhattacharya; Youcef M Rustum; David A Bellnier
Journal:  Neoplasia       Date:  2006-07       Impact factor: 5.715

4.  Enhancement of the action of the antivascular drug 5,6-dimethylxanthenone-4-acetic acid (DMXAA; ASA404) by non-steroidal anti-inflammatory drugs.

Authors:  L-C Steve Wang; Lai-Ming Ching; James W Paxton; Philip Kestell; Rachel Sutherland; Li Zhuang; Bruce C Baguley
Journal:  Invest New Drugs       Date:  2008-08-12       Impact factor: 3.850

5.  MRI-based characterization of vascular disruption by 5,6-dimethylxanthenone-acetic acid in gliomas.

Authors:  Mukund Seshadri; Michael J Ciesielski
Journal:  J Cereb Blood Flow Metab       Date:  2009-05-20       Impact factor: 6.200

6.  Use of an optimised enzyme/prodrug combination for Clostridia directed enzyme prodrug therapy induces a significant growth delay in necrotic tumours.

Authors:  Alexandra M Mowday; Ludwig J Dubois; Aleksandra M Kubiak; Jasmine V E Chan-Hyams; Christopher P Guise; Amir Ashoorzadeh; Philippe Lambin; David F Ackerley; Jeff B Smaill; Nigel P Minton; Jan Theys; Adam V Patterson
Journal:  Cancer Gene Ther       Date:  2021-02-08       Impact factor: 5.987

7.  Quantitative ultrasound imaging of therapy response in bladder cancer in vivo.

Authors:  William T Tran; Lakshmanan Sannachi; Naum Papanicolau; Hadi Tadayyon; Azza Al Mahrouki; Ahmed El Kaffas; Alborz Gorjizadeh; Justin Lee; Gregory J Czarnota
Journal:  Oncoscience       Date:  2016-04-18
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.